Heart valve procedure safety test: can common drug reduce dangerous bleeding?
NCT ID NCT05774691
Summary
This study aims to find the safest way to use a drug called protamine after a minimally invasive heart valve replacement (TAVI). Protamine helps reduce bleeding but can cause severe allergic reactions. Researchers will compare giving protamine to every patient versus only giving it to patients who need it, to see which approach better prevents death or serious bleeding within 30 days after the procedure.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AORTIC VALVE STENOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
A.S.Z. Aalst
RECRUITINGAalst, Belgium
Contact
-
Amsterdam University Medical Center
NOT_YET_RECRUITINGAmsterdam, Netherlands
Contact
-
Leiden University Medical Center
RECRUITINGLeiden, South Holland, Netherlands
Contact
Contact
-
Maastricht UMC
NOT_YET_RECRUITINGMaastricht, Limburg, Netherlands
Contact
-
St. Antonius Hospital
RECRUITINGNieuwegein, Utrecht, Netherlands
Contact
-
University Hospitals Leuven
RECRUITINGLeuven, Belgium
Contact
Conditions
Explore the condition pages connected to this study.